Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Thursday the availability of Trientine Hydrochloride Capsules USP in 250 mg.
The US Food and Drug Administration (FDA) approved Trientine Hydrochloride Capsules USP in 250 mg are a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules. The product can be stored at room temperature (20°C to 25°C or 68°F to 77°F) throughout the product shelf life of 24 months.
Dr. Reddy's Trientine Hydrochloride Capsules USP in 250 mg are available in 100 count bottles.
For the most recent 12 months ended December 2019, the Syprine brand and generic products had US sales of approximately USD94.2m MAT, according to IMS Health. Syprine is a trademark of Alton Pharma.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules